# Netflix Inc: financial statements, quarterly

NFLX · Nasdaq · CIK 1065280 · [Communication](/sectors/communication.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nflx.md) · [Financials](/companies/nflx/financials.md) · [Filings](/companies/nflx/filings.md) · [Insiders](/companies/nflx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nflx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [8.8 d](/filings/0001065280-26-000034.md) | [9.4](/filings/0001065280-25-000176.md) | [9.6](/filings/0001065280-25-000323.md) | [9.8](/filings/0001065280-25-000406.md) | [10.2 d](/filings/0001065280-26-000034.md) | [10.5](/filings/0001065280-26-000138.md) | [11.1](/filings/0001065280-26-000212.md) | [11.5](/filings/0001065280-26-000291.md) | [12.1 d](/filings/0001065280-26-000034.md) | [12.2](/filings/0001065280-26-000138.md) | [12.6](/filings/0001065280-26-000212.md) | [12.9](/filings/0001065280-26-000291.md) |
| Cost of revenue | $bn | [5.3 d](/filings/0001065280-26-000034.md) | [5.0](/filings/0001065280-25-000176.md) | [5.2](/filings/0001065280-25-000323.md) | [5.1](/filings/0001065280-25-000406.md) | [5.8 d](/filings/0001065280-26-000034.md) | [5.3](/filings/0001065280-26-000138.md) | [5.3](/filings/0001065280-26-000212.md) | [6.2](/filings/0001065280-26-000291.md) | [6.5 d](/filings/0001065280-26-000034.md) | [5.9](/filings/0001065280-26-000138.md) | [6.0](/filings/0001065280-26-000212.md) | [6.1](/filings/0001065280-26-000291.md) |
| Gross profit | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $bn | [0.7 d](/filings/0001065280-26-000034.md) | [0.7](/filings/0001065280-25-000176.md) | [0.7](/filings/0001065280-25-000323.md) | [0.7](/filings/0001065280-25-000406.md) | [0.8 d](/filings/0001065280-26-000034.md) | [0.8](/filings/0001065280-26-000138.md) | [0.8](/filings/0001065280-26-000212.md) | [0.9](/filings/0001065280-26-000291.md) | [0.9 d](/filings/0001065280-26-000034.md) | [1.0](/filings/0001065280-26-000138.md) | [1.0](/filings/0001065280-26-000212.md) | [1.0](/filings/0001065280-26-000291.md) |
| Operating income | $bn | [1.5 d](/filings/0001065280-26-000034.md) | [2.6](/filings/0001065280-25-000176.md) | [2.6](/filings/0001065280-25-000323.md) | [2.9](/filings/0001065280-25-000406.md) | [2.3 d](/filings/0001065280-26-000034.md) | [3.3](/filings/0001065280-26-000138.md) | [3.8](/filings/0001065280-26-000212.md) | [3.2](/filings/0001065280-26-000291.md) | [3.0 d](/filings/0001065280-26-000034.md) | [4.0](/filings/0001065280-26-000138.md) | [4.2](/filings/0001065280-26-000212.md) | [4.5](/filings/0001065280-26-000291.md) |
| Interest expense | $bn | [0.2 d](/filings/0001065280-24-000030.md) | [0.2](/filings/0001065280-24-000128.md) | [0.2](/filings/0001065280-24-000200.md) | [0.2](/filings/0001065280-24-000287.md) | [0.2 d](/filings/0001065280-26-000034.md) | [0.2](/filings/0001065280-26-000138.md) | [0.2](/filings/0001065280-26-000212.md) | [0.2](/filings/0001065280-26-000291.md) | [0.2 d](/filings/0001065280-26-000034.md) | [0.3](/filings/0001065280-26-000138.md) | [0.2](/filings/0001065280-26-000212.md) | [0.2](/filings/0001065280-26-000291.md) |
| Income tax | $bn | [0.2 d](/filings/0001065280-26-000034.md) | [0.3](/filings/0001065280-25-000176.md) | [0.4](/filings/0001065280-25-000323.md) | [0.3](/filings/0001065280-25-000406.md) | [0.3 d](/filings/0001065280-26-000034.md) | [0.3](/filings/0001065280-26-000138.md) | [0.5](/filings/0001065280-26-000212.md) | [0.6](/filings/0001065280-26-000291.md) | [0.3 d](/filings/0001065280-26-000034.md) | [1.3](/filings/0001065280-26-000138.md) | [0.7](/filings/0001065280-26-000212.md) | [0.7](/filings/0001065280-26-000291.md) |
| Net income | $bn | [0.9 d](/filings/0001065280-26-000034.md) | [2.3](/filings/0001065280-25-000176.md) | [2.1](/filings/0001065280-25-000323.md) | [2.4](/filings/0001065280-25-000406.md) | [1.9 d](/filings/0001065280-26-000034.md) | [2.9](/filings/0001065280-26-000138.md) | [3.1](/filings/0001065280-26-000212.md) | [2.5](/filings/0001065280-26-000291.md) | [2.4 d](/filings/0001065280-26-000034.md) | [5.3](/filings/0001065280-26-000138.md) | [3.4](/filings/0001065280-26-000212.md) | [3.7](/filings/0001065280-26-000291.md) |
| Diluted EPS | $ per share | not reported | [5.28](/filings/0001065280-25-000176.md) | [4.88](/filings/0001065280-25-000323.md) | [5.40](/filings/0001065280-25-000406.md) | not reported | [0.66](/filings/0001065280-26-000138.md) | [0.72](/filings/0001065280-26-000212.md) | [0.59](/filings/0001065280-26-000291.md) | not reported | [1.23](/filings/0001065280-26-000138.md) | [0.80](/filings/0001065280-26-000212.md) | [0.87](/filings/0001065280-26-000291.md) |
| Basic EPS | $ per share | not reported | [5.40](/filings/0001065280-25-000176.md) | [4.99](/filings/0001065280-25-000323.md) | [5.52](/filings/0001065280-25-000406.md) | not reported | [0.68](/filings/0001065280-26-000138.md) | [0.74](/filings/0001065280-26-000212.md) | [0.60](/filings/0001065280-26-000291.md) | not reported | [1.25](/filings/0001065280-26-000138.md) | [0.81](/filings/0001065280-26-000212.md) | [0.89](/filings/0001065280-26-000291.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [7.1](/filings/0001065280-25-000044.md) | [7.0](/filings/0001065280-24-000128.md) | [6.6](/filings/0001065280-24-000200.md) | [7.5](/filings/0001065280-24-000287.md) | [7.8](/filings/0001065280-26-000034.md) | [7.2](/filings/0001065280-25-000176.md) | [8.2](/filings/0001065280-25-000323.md) | [9.3](/filings/0001065280-25-000406.md) | [9.0](/filings/0001065280-26-000291.md) | [12.3](/filings/0001065280-26-000138.md) | [9.1](/filings/0001065280-26-000212.md) | [8.2](/filings/0001065280-26-000291.md) |
| Current assets | $bn | [9.9](/filings/0001065280-25-000044.md) | [9.9](/filings/0001065280-24-000128.md) | [9.6](/filings/0001065280-24-000200.md) | [12.1](/filings/0001065280-24-000287.md) | [13.1](/filings/0001065280-26-000034.md) | [11.7](/filings/0001065280-25-000176.md) | [12.0](/filings/0001065280-25-000323.md) | [13.0](/filings/0001065280-25-000406.md) | [13.0](/filings/0001065280-26-000291.md) | [17.1](/filings/0001065280-26-000138.md) | [13.9](/filings/0001065280-26-000212.md) | [13.2](/filings/0001065280-26-000291.md) |
| Total assets | $bn | [48.7](/filings/0001065280-25-000044.md) | [48.8](/filings/0001065280-24-000128.md) | [49.1](/filings/0001065280-24-000200.md) | [52.3](/filings/0001065280-24-000287.md) | [53.6](/filings/0001065280-26-000034.md) | [52.1](/filings/0001065280-25-000176.md) | [53.1](/filings/0001065280-25-000323.md) | [54.9](/filings/0001065280-25-000406.md) | [55.6](/filings/0001065280-26-000291.md) | [61.0](/filings/0001065280-26-000138.md) | [58.5](/filings/0001065280-26-000212.md) | [58.7](/filings/0001065280-26-000291.md) |
| Current liabilities | $bn | [8.9](/filings/0001065280-25-000044.md) | [9.3](/filings/0001065280-24-000128.md) | [10.1](/filings/0001065280-24-000200.md) | [10.7](/filings/0001065280-24-000287.md) | [10.8](/filings/0001065280-26-000034.md) | [9.7](/filings/0001065280-25-000176.md) | [8.9](/filings/0001065280-25-000323.md) | [9.7](/filings/0001065280-25-000406.md) | [11.0](/filings/0001065280-26-000291.md) | [12.1](/filings/0001065280-26-000138.md) | [12.1](/filings/0001065280-26-000212.md) | [12.3](/filings/0001065280-26-000291.md) |
| Total liabilities | $bn | [28.1](/filings/0001065280-25-000044.md) | [27.5](/filings/0001065280-24-000128.md) | [27.0](/filings/0001065280-24-000200.md) | [29.6](/filings/0001065280-24-000287.md) | [28.9](/filings/0001065280-26-000034.md) | [28.1](/filings/0001065280-25-000176.md) | [28.1](/filings/0001065280-25-000323.md) | [29.0](/filings/0001065280-25-000406.md) | [29.0](/filings/0001065280-26-000291.md) | [29.9](/filings/0001065280-26-000138.md) | [28.3](/filings/0001065280-26-000212.md) | [29.4](/filings/0001065280-26-000291.md) |
| Long-term debt | $bn | [14.1](/filings/0001065280-25-000044.md) | [13.2](/filings/0001065280-24-000128.md) | [12.2](/filings/0001065280-24-000200.md) | [14.2](/filings/0001065280-24-000287.md) | [13.8](/filings/0001065280-26-000034.md) | [14.0](/filings/0001065280-25-000176.md) | [14.5](/filings/0001065280-25-000323.md) | [14.5](/filings/0001065280-25-000406.md) | [13.5](/filings/0001065280-26-000291.md) | [13.4](/filings/0001065280-26-000138.md) | [11.8](/filings/0001065280-26-000212.md) | [12.7](/filings/0001065280-26-000291.md) |
| Short-term borrowings | $bn | [0.4](/filings/0001065280-25-000044.md) | [0.8](/filings/0001065280-24-000128.md) | [1.8](/filings/0001065280-24-000200.md) | [1.8](/filings/0001065280-24-000287.md) | [1.8](/filings/0001065280-26-000034.md) | [1.0](/filings/0001065280-25-000176.md) | [0.0](/filings/0001065280-25-000323.md) | [0.0](/filings/0001065280-25-000406.md) | [1.0](/filings/0001065280-26-000291.md) | [1.0](/filings/0001065280-26-000138.md) | [2.5](/filings/0001065280-26-000212.md) | [2.5](/filings/0001065280-26-000291.md) |
| Shareholders' equity | $bn | [20.6](/filings/0001065280-26-000034.md) | [21.4](/filings/0001065280-25-000323.md) | [22.1](/filings/0001065280-25-000406.md) | [22.7](/filings/0001065280-25-000406.md) | [24.7](/filings/0001065280-26-000291.md) | [24.0](/filings/0001065280-26-000212.md) | [25.0](/filings/0001065280-26-000291.md) | [26.0](/filings/0001065280-26-000291.md) | [26.6](/filings/0001065280-26-000291.md) | [31.1](/filings/0001065280-26-000212.md) | [30.2](/filings/0001065280-26-000291.md) | [29.3](/filings/0001065280-26-000291.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1,663 d](/filings/0001065280-26-000034.md) | [2,213](/filings/0001065280-25-000176.md) | [1,291](/filings/0001065280-25-000323.md) | [2,321](/filings/0001065280-25-000406.md) | [1,537 d](/filings/0001065280-26-000034.md) | [2,789](/filings/0001065280-26-000138.md) | [2,423](/filings/0001065280-26-000212.md) | [2,825](/filings/0001065280-26-000291.md) | [2,112 d](/filings/0001065280-26-000034.md) | [5,290](/filings/0001065280-26-000138.md) | [1,744](/filings/0001065280-26-000212.md) | [3,162](/filings/0001065280-26-000291.md) |
| Capital expenditure | $m | [81.6 d](/filings/0001065280-26-000034.md) | [75.7](/filings/0001065280-25-000176.md) | [78.3](/filings/0001065280-25-000323.md) | [127](/filings/0001065280-25-000406.md) | [159 d](/filings/0001065280-26-000034.md) | [128](/filings/0001065280-26-000138.md) | [156](/filings/0001065280-26-000212.md) | [165](/filings/0001065280-26-000291.md) | [239 d](/filings/0001065280-26-000034.md) | [196](/filings/0001065280-26-000138.md) | [219](/filings/0001065280-26-000212.md) | [279](/filings/0001065280-26-000291.md) |
| Share repurchases | $m | [2,500 d](/filings/0001065280-26-000034.md) | [2,000](/filings/0001065280-25-000176.md) | [1,600](/filings/0001065280-25-000323.md) | [1,700](/filings/0001065280-25-000406.md) | [964 d](/filings/0001065280-26-000034.md) | [3,536](/filings/0001065280-26-000138.md) | [1,654](/filings/0001065280-26-000212.md) | [1,857](/filings/0001065280-26-000291.md) | [2,080 d](/filings/0001065280-26-000034.md) | [1,271](/filings/0001065280-26-000138.md) | [4,714](/filings/0001065280-26-000212.md) | [4,797](/filings/0001065280-26-000291.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [452](/filings/0001065280-24-000128.md) | [452](/filings/0001065280-24-000200.md) | [450](/filings/0001065280-24-000287.md) | [442](/filings/0001065280-25-000176.md) | [440](/filings/0001065280-25-000323.md) | [438](/filings/0001065280-25-000406.md) | [4,370](/filings/0001065280-26-000138.md) | [4,349](/filings/0001065280-26-000212.md) | [4,340](/filings/0001065280-26-000291.md) | [4,298](/filings/0001065280-26-000138.md) | [4,261](/filings/0001065280-26-000212.md) | [4,195](/filings/0001065280-26-000291.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,106,325,903 at 2026-09-30, from the cover of the [10-Q filed 2026-10-21](/filings/0001065280-26-000291.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.